Drugs / Zofin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05643729 | Nov 2023 → May 2024 | chronic obstructive pulmonary disease | ZEO ScientifiX, Inc. | Suspended | No outcome recorded |
| Phase 1/2 | NCT05228899 | Apr 2022 → Oct 2023 | COVID-19 | ZEO ScientifiX, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04384445 | Sep 2020 → Jul 2023 | COVID-19, acute respiratory distress syndrome, severe acute respiratory syndrome | ZEO ScientifiX, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04657406 | — | COVID-19, acute respiratory distress syndrome, severe acute respiratory syndrome | ZEO ScientifiX, Inc. | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zofin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05228899 ↗ |
| Known as | OrganicellTM Flow | “This is an open label expanded access protocol to treat subjects using ZofinTM (OrganicellTM Flow) for treatment of mild to moderate COVID-19 due to SARS-Cov-2.” NCT04657406 ↗ |
| Modality | Other / unclassified | “Zofin is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF).” NCT04657406 ↗ |
| Route | Intravenous | “Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care.” NCT04384445 ↗ |